
Drugmaker Biogen's shares BIIB.O fall 1.32% to $137.55 premarket
Co forecasts 2025 adj. profit between $15.25/shr and $16.25/shr, below analyst est. of $16.34/shr, according to data compiled by LSEG
Co reports Q4 profit of $3.44/shr, higher than analyst est. of $3.35/shr
BIIB said it expects revenue to decline by a mid-single digit percentage in 2025 compared to 2024
Co posts 2024 rev. of $9.68 bln, down 2% from a year earlier
Stock fell ~42% in the last 12 months